Additional file 5 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Osuga, Yutaka, Seki, Yoshifumi, Tanimoto, Masataka, Kusumoto, Takeru, Kudou, Kentarou, Terakawa, Naoki
2021 · doi:10.6084/m9.figshare.14821141 · W6939679861
article OA: green CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-19 ⓘ

This study summarizes pharmacodynamic parameters at each assessment point for relugolix, an oral GnRH receptor antagonist, in women with endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Additional file 5. Summary of pharmacodynamic parameters at each assessment point.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Source provenance

openalex
last seen: 2026-05-13T18:33:16.088889+00:00
License: CC0 · commercial use OK